Vertex Pharmaceuticals (VRTX) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 1, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Nancy Thornberry, Director sold 1,000 shares at $547.86 ($548K).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All VRTX insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
VRTX insider transactions (Form 4)
Open-market purchases and sales. 98 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Nancy ThornberryDirector | Sell Plan | 1,0001,109 held (−47%) | $547.86 | $548K | -6.0% | — |
| Nov 18SEC | Sangeeta N. BhatiaDirector | Sell Plan | 2714,653 held (−6%) | $547.86 | $148K | -6.0% | — |
| Nov 16SEC | Charles F. Wagner Jr.Evp, Co & Fo | Sell Plan | 15,28631,764 held (−32%) | $547.87 | $8.4M | -6.0% | — |
| Nov 10SEC | Reshma KewalramaniCEO, President | Sell Plan | 11,86686,471 held (−12%) | $531.53 | $6.3M | -3.1% | — |
| Jul 7SEC | Duncan McKechnieEvp, Chief Commercial Officer | Sell Plan | 1,54111,001 held (−12%) | $519.00 | $800K | -0.8% | — |
| Jul 7SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 1,50045,321 held (−3%) | $524.99 | $787K | -1.9% | — |
| Jul 6SEC | Joy LiuGeneral Counsel | Sell Plan | 82819,131 held (−4%) | $502.71 | $416K | +2.4% | — |
| Jun 30SEC | Carmen BozicEvp And Cmo | Sell Plan | 59615,337 held (−4%) | $482.50 | $288K | +6.7% | — |
| Jun 23SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,02015,933 held (−6%) | $462.17 | $471K | +11.4% | — |
| Jun 17SEC | Carmen BozicEvp And Cmo | Sell Plan | 4,06216,953 held (−19%) | $450.00 | $1.8M | +14.4% | — |
| Jun 9SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,74521,015 held (−8%) | $450.00 | $785K | +14.4% | — |
| Jun 3SEC | Joy LiuGeneral Counsel | Sell Plan | 82819,959 held (−4%) | $439.91 | $364K | +17.1% | — |
| Jun 2SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,97422,760 held (−8%) | $450.00 | $888K | +14.4% | — |
| May 19SEC | Carmen BozicEvp And Cmo | Sell Plan | 1,35424,734 held (−5%) | $453.45 | $614K | +13.6% | — |
| May 19SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 337,284 held (−0%) | $453.45 | $15K | +13.6% | — |
| May 14SEC | Carmen BozicEvp And Cmo | Sell Plan | 6,98826,088 held (−21%) | $450.00 | $3.1M | +14.4% | — |
| May 5SEC | Joy LiuGeneral Counsel | Sell Plan | 1,10420,729 held (−5%) | $425.02 | $469K | +21.2% | — |
| May 5SEC | Sangeeta N. BhatiaDirector | Sell Plan | 3184,924 held (−6%) | $423.73 | $135K | +21.5% | — |
| Apr 3SEC | Joy LiuGeneral Counsel | Sell Plan | 97821,833 held (−4%) | $449.17 | $439K | +14.7% | — |
| Mar 31SEC | Carmen BozicEvp And Cmo | Sell Plan | 2,32933,076 held (−7%) | $450.95 | $1.1M | +14.2% | — |
| Mar 17SEC | Carmen BozicEvp And Cmo | Sell Plan | 2,32935,405 held (−6%) | $481.79 | $1.1M | +6.9% | — |
| Mar 13SEC | Duncan McKechnieEvp, Chief Commercial Officer | Sell Plan | 2,63312,489 held (−17%) | $498.42 | $1.3M | +3.3% | — |
| Mar 6SEC | Duncan McKechnieEvp, Chief Commercial Officer | Sell Plan | 2,43715,122 held (−14%) | $475.30 | $1.2M | +8.4% | — |
| Mar 4SEC | Joy LiuGeneral Counsel | Sell Plan | 89222,811 held (−4%) | $495.96 | $442K | +3.8% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 15,580105,998 held (−13%) | $495.38 | $7.7M | +4.0% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 5,995100,003 held (−6%) | $496.16 | $3.0M | +3.8% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 3,498121,578 held (−3%) | $494.33 | $1.7M | +4.2% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 3,278131,730 held (−2%) | $488.27 | $1.6M | +5.5% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 2,725128,545 held (−2%) | $490.54 | $1.3M | +5.0% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 2,520125,076 held (−2%) | $493.29 | $1.2M | +4.4% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 2,510135,008 held (−2%) | $487.13 | $1.2M | +5.7% | — |
| Mar 3SEC | Carmen BozicEvp And Cmo | Sell Plan | 2,32937,734 held (−6%) | $480.31 | $1.1M | +7.2% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 1,72598,278 held (−2%) | $496.95 | $857K | +3.6% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 949127,596 held (−1%) | $491.30 | $466K | +4.8% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 460131,270 held (−0%) | $489.32 | $225K | +5.3% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 400137,878 held (−0%) | $479.75 | $192K | +7.4% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 240137,518 held (−0%) | $482.84 | $116K | +6.7% | — |
| Mar 3SEC | Reshma KewalramaniCEO, President | Sell Plan | 120137,758 held (−0%) | $481.50 | $58K | +7.0% | — |
| Mar 2SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 3576,624 held (−5%) | $483.36 | $173K | +6.5% | — |
| Feb 26SEC | Duncan McKechnieEvp, Chief Commercial Officer | Sell Plan | 2,50019,969 held (−11%) | $486.35 | $1.2M | +5.9% | — |
| Feb 26SEC | Duncan McKechnieEvp, Chief Commercial Officer | Sell Plan | 2,41017,559 held (−12%) | $489.00 | $1.2M | +5.3% | — |
| Feb 26SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 1,84655,570 held (−3%) | $486.35 | $898K | +5.9% | — |
| Feb 26SEC | Jonathan BillerGeneral Counsel | Sell Plan | 94513,659 held (−6%) | $486.35 | $460K | +5.9% | — |
| Feb 26SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 66818,432 held (−3%) | $486.35 | $325K | +5.9% | — |
| Feb 26SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 6207,284 held (−8%) | $486.35 | $302K | +5.9% | — |
| Feb 26SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 26046,763 held (−1%) | $486.35 | $126K | +5.9% | — |
| Feb 26SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 2236,981 held (−3%) | $486.35 | $108K | +5.9% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 19,66282,124 held (−19%) | $468.57 | $9.2M | +9.9% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 11,71263,171 held (−16%) | $470.54 | $5.5M | +9.5% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 10,263101,786 held (−9%) | $467.75 | $4.8M | +10.1% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 7,24174,883 held (−9%) | $469.61 | $3.4M | +9.7% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 4,23758,934 held (−7%) | $471.43 | $2.0M | +9.2% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 2,730113,897 held (−2%) | $465.05 | $1.3M | +10.7% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 1,848112,049 held (−2%) | $465.80 | $861K | +10.6% | — |
| Feb 23SEC | Amit SachdevEvp Chief Patient & Ext Af Off | Sell Plan | 920116,627 held (−1%) | $463.91 | $427K | +11.0% | — |
| Feb 19SEC | Jonathan BillerGeneral Counsel | Sell Plan | 2,47616,992 held (−13%) | $489.46 | $1.2M | +5.2% | — |
| Feb 19SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 2,4379,668 held (−20%) | $489.46 | $1.2M | +5.2% | — |
| Feb 19SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 2,03121,544 held (−9%) | $489.46 | $994K | +5.2% | — |
| Feb 19SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 1,5578,388 held (−16%) | $489.46 | $762K | +5.2% | — |
| Feb 19SEC | Jonathan BillerGeneral Counsel | Sell Plan | 1,24415,748 held (−7%) | $473.68 | $589K | +8.7% | — |
| Feb 19SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 1,1828,486 held (−12%) | $473.68 | $560K | +8.7% | — |
| Feb 19SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 81720,727 held (−4%) | $473.68 | $387K | +8.7% | — |
| Feb 19SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 6387,750 held (−8%) | $473.68 | $302K | +8.7% | — |
| Feb 19SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 60949,018 held (−1%) | $489.46 | $298K | +5.2% | — |
| Feb 19SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 36848,650 held (−1%) | $473.68 | $174K | +8.7% | — |
| Feb 18SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 1,50046,132 held (−3%) | $499.99 | $750K | +3.0% | — |
| Feb 18SEC | Jonathan BillerGeneral Counsel | Sell Plan | 98816,838 held (−6%) | $499.00 | $493K | +3.2% | — |
| Feb 18SEC | Sangeeta N. BhatiaDirector | Sell Plan | 2664,299 held (−6%) | $500.00 | $133K | +3.0% | — |
| Feb 12SEC | Mark E. BunnageEvp, Chief Scientific Officer | Sell Plan | 2,02112,914 held (−14%) | $460.43 | $931K | +11.9% | — |
| Feb 12SEC | Jonathan BillerGeneral Counsel | Sell Plan | 1,92520,819 held (−8%) | $460.43 | $886K | +11.9% | — |
| Feb 12SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 1,75122,046 held (−7%) | $460.43 | $806K | +11.9% | — |
| Feb 12SEC | Kristen AmbroseSvp & Chief Accounting Officer | Sell Plan | 1,37610,127 held (−12%) | $460.43 | $634K | +11.9% | — |
| Feb 12SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 46651,436 held (−1%) | $460.43 | $215K | +11.9% | — |
| Jan 9SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 4,50042,293 held (−10%) | $474.99 | $2.1M | +8.4% | — |
| Jan 8SEC | Charles F. Wagner Jr.Evp, Co & Fo | Sell Plan | 9,53237,725 held (−20%) | $461.00 | $4.4M | +11.7% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 15,68136,456 held (−30%) | $452.20 | $7.1M | +13.9% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 10,36026,096 held (−28%) | $453.34 | $4.7M | +13.6% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 7,89967,298 held (−11%) | $445.56 | $3.5M | +15.6% | — |
| Dec 5SEC | Charles F. Wagner Jr.Evp, Co & Fo | Sell Plan | 7,00037,725 held (−16%) | $461.00 | $3.2M | +11.7% | — |
| Dec 5SEC | Charles F. Wagner Jr.Evp, Co & Fo | Sell Plan | 7,00044,725 held (−14%) | $451.00 | $3.2M | +14.2% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 5,88057,946 held (−9%) | $449.84 | $2.6M | +14.5% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 5,80952,137 held (−10%) | $451.20 | $2.6M | +14.1% | — |
| Dec 5SEC | Ourania TatsisEvp, Chief Reg. & Quality Off. | Sell Plan | 4,50046,793 held (−9%) | $449.99 | $2.0M | +14.5% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 4,46983,338 held (−5%) | $440.40 | $2.0M | +16.9% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 4,35275,197 held (−5%) | $444.36 | $1.9M | +15.9% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 2,46979,549 held (−3%) | $443.21 | $1.1M | +16.2% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 2,32063,826 held (−4%) | $448.78 | $1.0M | +14.8% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 2,07024,026 held (−8%) | $455.22 | $942K | +13.1% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 1,32082,018 held (−2%) | $441.26 | $582K | +16.7% | — |
| Dec 5SEC | Jeffrey M. LeidenChair | Sell Plan | 1,15266,146 held (−2%) | $447.05 | $515K | +15.2% | — |
| Dec 5SEC | Jonathan BillerGeneral Counsel | Sell Plan | 34715,306 held (−2%) | $449.00 | $156K | +14.7% | — |
| Nov 19SEC | Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | Sell Plan | 2,50016,852 held (−13%) | $434.58 | $1.1M | +18.5% | — |
| Nov 17SEC | Jeffrey M. LeidenChair | Sell Plan | 32,23445,396 held (−42%) | $440.30 | $14.2M | +17.0% | — |
| Nov 17SEC | Jeffrey M. LeidenChair | Sell Plan | 21,33024,066 held (−47%) | $441.35 | $9.4M | +16.7% | — |
| Nov 17SEC | Jeffrey M. LeidenChair | Sell Plan | 18,52825,186 held (−42%) | $440.22 | $8.2M | +17.0% | — |
| Nov 17SEC | Jeffrey M. LeidenChair | Sell Plan | 1,16024,026 held (−5%) | $441.05 | $512K | +16.8% | — |
| Nov 17SEC | Jeffrey M. LeidenChair | Sell Plan | 4024,026 held (−0%) | $442.00 | $18K | +16.5% | — |
| Oct 3SEC | Jonathan BillerGeneral Counsel | Sell Plan | 69415,653 held (−4%) | $404.21 | $281K | +27.4% | — |
Similar past setups: not applicable. VRTX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with VRTX in the Research Lab
VRTX has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Vertex Pharmaceuticals insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 14 sold $140M of VRTX stock on the open market; P/E 37.6 vs. a sector median of 24.5.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
VRTX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $15.4M | 4 |
| Q3 2026 | — | 0 | $2.0M | 3 |
| Q2 2026 | — | 0 | $9.4M | 12 |
| Q1 2026 | — | 0 | $76.1M | 56 |
| Q4 2025 | — | 0 | $70.9M | 23 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Vertex Pharmaceuticals insiders reported open-market purchases totaling $0, while 14 insiders reported sales totaling $140M. 98 of 98 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
VRTX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 2, 2026 | +9.9% | None | -5.0%S&P -0.2% | pending |
| Aug 3, 2026 | -1.8% | None | +0.3%S&P +3.3% | +16.6% |
| May 4, 2026 | -2.7% | Sold $469K | +0.1%S&P +0.4% | +4.1% |
| Feb 12, 2026 | -2.7% | Sold $3.5M | +6.6%S&P -1.5% | -4.5% |
| Nov 3, 2025 | +4.2% | None | -0.9%S&P -1.0% | +8.5% |
| Aug 4, 2025 | -0.2% | None | -18.9%S&P +1.0% | +5.9% |
| May 5, 2025 | +2.5% | None | -10.2%S&P -1.4% | -1.4% |
| Feb 10, 2025 | +6.7% | None | -3.0%S&P +0.8% | +10.5% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
VRTX short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded VRTX
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Thomas H TubervilleSenate | Sold $1,001 - $15,000 | May 3, 2024 | Aug 5, 2026 | +28.4% |
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +18.9% |
Insiders at Vertex Pharmaceuticals
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Jeffrey M. LeidenChair | — | $60.9M | Feb 26, 2026 | — | — |
| Amit SachdevEvp Chief Patient & Ext Af Off | — | $28.4M | Jul 23, 2026 | — | — |
| Reshma KewalramaniCEO, President | — | $26.0M | Nov 10, 2026 | — | — |
| Charles F. Wagner Jr.Evp, Co & Fo | — | $19.2M | Nov 16, 2026 | — | — |
| Carmen BozicEvp And Cmo | — | $11.3M | Jun 30, 2026 | — | — |
| Ourania TatsisEvp, Chief Reg. & Quality Off. | — | $6.5M | Jul 23, 2026 | — | — |
| Duncan McKechnieEvp, Chief Commercial Officer | — | $5.7M | Jul 7, 2026 | — | — |
| Jonathan BillerGeneral Counsel | — | $4.1M | Feb 26, 2026 | — | — |
| Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. | — | $3.6M | Feb 26, 2026 | — | — |
| Mark E. BunnageEvp, Chief Scientific Officer | — | $3.0M | May 19, 2026 | — | — |
| Joy LiuGeneral Counsel | — | $2.1M | Jul 6, 2026 | — | — |
| Kristen AmbroseSvp & Chief Accounting Officer | — | $2.0M | Sep 1, 2026 | — | — |
| Nancy ThornberryDirector | — | $548K | Nov 18, 2026 | — | — |
| Sangeeta N. BhatiaDirector | — | $416K | Nov 18, 2026 | — | — |
| Daniel J. BrennanDirector | — | — | Oct 22, 2026 | — | — |
| Grunsven Jasper VanEvp, Cp And Nppo | — | — | Sep 10, 2026 | — | — |
| Bruce I. SachsDirector | — | — | Aug 31, 2026 | — | — |
| Alan M. GarberDirector | — | — | May 5, 2026 | — | — |
| Diana McKenzieDirector | — | — | May 5, 2026 | 1 of 1 | — |
| Jennifer SchneiderDirector | — | — | May 5, 2026 | — | — |
| Suketu UpadhyayDirector | — | — | May 5, 2026 | — | — |
| David AltshulerEvp, Chief Scientific Officer | — | — | Jan 26, 2026 | — | — |
| Lloyd CarneyDirector | — | — | Nov 20, 2025 | — | — |
Board links: companies that share insiders with VRTX
Directors and executives who filed Form 4s for VRTX and another company in the last 12 months.
- DNLIDenali Therapeutics Nancy Thornberry Director here · Director at DNLI · latest filing Nov 18, 2026
- GDYNGrid Dynamics Holdings Lloyd Carney Director here · Director at GDYN · latest filing Nov 9, 2026
- INCYIncyte Suketu Upadhyay Director here · CFO at INCY · latest filing May 6, 2026
- METMetLife Diana McKenzie Director here · Director at MET · latest filing Oct 5, 2026
- ODTXOdyssey Therapeutics Jeffrey M. Leiden Chair here · Director at ODTX · latest filing May 11, 2026
- VVisa Lloyd Carney Director here · Director at V · latest filing Nov 2, 2026
- WATWaters Daniel J. Brennan Director here · Director at WAT · latest filing Oct 22, 2026
- ZBHZimmer Biomet Suketu Upadhyay Director here · CFO at ZBH · latest filing May 5, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
VRTX stock: common questions
Are Vertex Pharmaceuticals insiders buying VRTX stock?
No. No Vertex Pharmaceuticals insider reported an open-market purchase of VRTX in the past 12 months.
Are Vertex Pharmaceuticals insiders selling VRTX stock?
14 insiders reported sales worth $140M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is VRTX's P/E ratio?
VRTX trades at about 37.6 times trailing earnings, compared with a median of 24.5 for the Health Care sector.
What is VRTX's 52-week range?
Over the past year VRTX has traded between $422.32 and $558.88. It last closed at $515.02 on Nov 20, 2026.